That is another BIG reason why Pfizer should be looking to acquire AMRN. Imagine if Pfizer and Edding worked together on the promotion and distribution of BOTH Lipitor and Vascepa. The potential market for Vascepa in China is MASSIVE! Yet, I fear that it may never be optimized without a motivated and competent BP owning AMRN. The same can be said for Europe and the US. Given the experience Pfizer has with selling Lipitor in China, they should be a superb position to understand what they could do with Vascepa "if" they owned AMRN.